Clinical evaluation of fluticasone/formoterol twice daily delivered via a single dose dry powder inhaler in patients with persistent asthma
Jaideep Gogtay (Mumbai, Maharashtra, India), Pradyut Waghray, Mahip Saluja, Mayank Agarwal, Abhijit Vaidya, Jaideep Gogtay, Ashish Kumar Deb, Sneha Limaye, Ashish Goyal, Aloke Gopal Ghoshal, Sudhir Bhatnagar, Akash Balki, George Dsouza, Manish Kumar Jain, Sharad Tikkiwal, Sujeet Rajan, Raja Dhar
Source: International Congress 2016 – Asthma management
Session: Asthma management
Session type: Thematic Poster
Number: 4114
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Jaideep Gogtay (Mumbai, Maharashtra, India), Pradyut Waghray, Mahip Saluja, Mayank Agarwal, Abhijit Vaidya, Jaideep Gogtay, Ashish Kumar Deb, Sneha Limaye, Ashish Goyal, Aloke Gopal Ghoshal, Sudhir Bhatnagar, Akash Balki, George Dsouza, Manish Kumar Jain, Sharad Tikkiwal, Sujeet Rajan, Raja Dhar. Clinical evaluation of fluticasone/formoterol twice daily delivered via a single dose dry powder inhaler in patients with persistent asthma. Eur Respir J 2016; 48: Suppl. 60, 4114
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Equivalence of an innovative multidose salmeterol/fluticasone dry powder inhaler vs comparator in paediatric asthma Source: Annual Congress 2013 –Asthma treatment and management in children Year: 2013
A single-dose double-blind study comparing efficacy of two dry powder inhalers containing budesonide and formoterol in asthmatic patients Source: International Congress 2016 – Asthma management Year: 2016
Broncho dilator response to salbutamol delivered by metered dose inhaler with spacer versus dry powder inhaler in acute asthma in children Source: International Congress 2016 – Drugs, bugs, BMI, and other problems in paediatric asthma Year: 2016
High dose extrafine beclomethasone/formoterol via metered dose inhaler is effective and safe in asthmatics not controlled on medium-high dose of inhaled corticosteroids Source: International Congress 2014 – Asthma and COPD management Year: 2014
Use of a new dry powder inhaler to deliver umeclidinium/vilanterol in the treatment of COPD Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013
Ease of use of a two-strip dry powder inhaler (DPI) to deliver fluticasone furoate/vilanterol (FF/VI) and FF alone in asthma Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013
Cardiovascular safety of extrafine beclomethasone/formoterol (BDP/FF) delivered via a novel dry powder inhaler (NEXThaler®) in COPD patients Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015
Comparable effectiveness of budesonide/formoterol combination and fluticasone for the treatment of cough variant asthma Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013
Pharmacokinetic and pharmacodynamic evaluation after administration of beclomethasone dipropionate and formoterol fumarate as fixed or free metered-dose inhaler combination in adolescent asthma Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013
Comparison of HFA salmeterol-fluticasone (SFC) combination when given through breath actuated inhaler (BAI) and pressurised meter dose inhaler (pMDI) in patients with moderate-to-severe asthma Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013
Comparative efficacy and costs of the treatment of moderate to severe persistent asthma with a new dry-powder inhaled beclomethasone dipropionate and formoterol combination Source: Annual Congress 2013 –Health economics of airway diseases Year: 2013
Effect of switching from salmeterol/fluticasone dry powder inhaler to formoterol/fluticasone pressurized metered-dose inhaler in elderly asthma patients Source: International Congress 2016 – Asthma management Year: 2016
Budesonide/formoterol in a single inhaler once or twice daily provides better asthma control than inhaled fluticasone or budesonide alone in patients with moderate persistent asthma Source: Eur Respir J 2002; 20: Suppl. 38, 387s Year: 2002
Prescribed doses and effect on asthma treatment outcomes of extrafine (ciclesonide) vs standard particle inhaled corticosteroids (ICS) Source: International Congress 2015 – Novel targets and strategies for the treatment of cough, asthma, rhinosinusitis and COPD Year: 2015
Assessment of the bioequivalence of two DPIs containing fluticasone and salmeterol, in patients with controlled or partly controlled asthma Source: International Congress 2016 – Clinical characteristics of asthma Year: 2016
Scientific rationale for using a single inhaler for asthma control by comparison of the effectiveness and safety of formoterol/budesonide turbuhaler as physician-guided adjustable maintenance dosing regimen versus formoterol/budesonide given as fixed dose of twice daily therapy in the management of bronchial asthma Source: Annual Congress 2009 - Aspects of clinical asthma Year: 2009
Formoterol: a new pMDI CFC free formulation. Efficacy of the 12µg dosage versus a dry powder inhaler in moderate to severe asthmatic patients Source: Eur Respir J 2003; 22: Suppl. 45, 284s Year: 2003
Efficacy of tiotropium Respimat® in adults with moderate asthma, by baseline LTRA use Source: International Congress 2015 – Modulating the immune system in COPD and asthma Year: 2015
The budesonide/formoterol inhaler as maintenance and reliever therapy in Maori asthmatics Source: Annual Congress 2013 –Treatment and management of asthma in primary care Year: 2013
Prevalence of serious post-training inhaler technique errors made by device-naïve patients using three different dry powder inhalers (DPIs) Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections Year: 2015